S 3510119th CongressIn Committee

Biosimilar Inspection Modernization Act of 2025

Standard Summary
Balanced plain-English summary

This bill seeks to modernize Food and Drug Administration inspections of establishments that manufacture or process biosimilar biological products. It requires a public meeting and report on mutual recognition agreements, updates inspection tools to support risk-based and remote assessments, and requires a strategic plan to address domestic inspection challenges.

Key Points

  • 1Requires a public meeting within 180 days on using mutual recognition agreements for biosimilar establishment inspections.
  • 2Requires a report to Congress with recommendations on mutual recognition agreements for inspections.
  • 3Directs FDA to update inspection processes and expand risk-based tools, including remote regulatory assessments.
  • 4Requires a strategic plan within one year on improving domestic inspections of biosimilar biological product facilities.

Impact Areas

Biosimilar manufacturersFood and Drug AdministrationPatients relying on biosimilar productsForeign regulatory partnersCongressional health committees
Generated by deepseek/deepseek-v4.1-flash-1017Nov 18, 2026